A clinical study further confirms that luteolin (2 μmol/L) reduces IL-6 and TNF-α via TLR4/NF-κB signaling, supporting its potential in managing pediatric allergic asthma (Yu et al., 2019). This evidence concerns the gene NFKB1 and allergic asthma.